This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AMG 655
Description: AMG 655 is a fully human monoclonal agonist antibody that binds to the extracellular domain of human TRAIL (tumor necrosis factor (TNF)-related apoptosis-inducing ligand) receptor 2 (TR-2). AMG 655 has been seen to induce apoptosis in a variety of transformed human cell lines and its anti-tumor potential was confirmed in in vivo tumor xenograft models.
Deal Structure: In February 2008, Amgen granted Takeda an exclusive license to develop and commercialize in Japan certain of Amgens proprietary molecules in the same indications as currently being pursued by Amgen, with the potential for additional indications. The molecules under the Japan License Agreement include the following: AMG 108, AMG 317, AMG 386, AMG 479, AMG 655 and Vectibix (panitumumab), and six other molecules in clinical development, including one that may be included at Amgens option (collectively, the Products).
In respect of the Japan License Agreement, Takeda will pay to Amgen an upfront payment of $200 million and success-based development and regulatory approval milestone payments of up to $362 million. Takeda will also pay up to $340 million in expected worldwide development costs for the Products for 2008 through 2012, and a percentage of certain development costs for the Products thereafter. Takeda will be solely responsible for all development and commercialization...See full deal structure in Biomedtracker
Partners: Takeda Pharmaceutical Company Ltd
Additional information available to subscribers only: